Brimonidine-d_4 D-tartrate

Cat. No.: HY-B0659AS

CAS No.: 1316758-27-6

Molecular Formula: $C_{15}H_{12}D_4BrN_5O_6$

Molecular Weight: 446.25

Target: Adrenergic Receptor; Isotope-Labeled Compounds

Pathway: GPCR/G Protein; Neuronal Signaling; Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (112.04 mM; Need ultrasonic)

H2O : 25 mg/mL (56.02 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.2409 mL	11.2045 mL	22.4090 mL
5 mM	0.4482 mL	2.2409 mL	4.4818 mL
10 mM	0.2241 mL	1.1204 mL	2.2409 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Brimonidine-d_4 (D-tartrate) is the deuterium labeled Brimonidine D-tartrate[1].

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72(4): p. 413-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA